Table 3.
The relationships between intensity of JAK1expression and clinicopathological parameters in vitiligo patients
| Clinicopathological parameter | Mild (n = 18) | Moderate (n = 9) | Strong (n = 12) | Statistical test | p-value |
|---|---|---|---|---|---|
| Age (yr) | |||||
| Mean ± SD | 37.00 ± 17.60 | 38.33 ± 12.76 | 29.33 ± 11.57 | 3.48a | .170 |
| Median (range) | 35.00 (18–64) | 33.00 (27–55) | 22.00 (21–45) | ||
| Disease duration (yr) | |||||
| Mean ± SD | 5.67 ± 4.35 | 6.00 ± 3.00 | 3.67 ± 2.46 | 6.53a | .030* |
| Median (range) | 4.00 (3–15) | 4.00 (4–10) | |||
| Sex | 11.44b | .003* | |||
| Male | 12 (66.7) | 0 | 4 (33.3) | ||
| Female | 6 (33.3) | 9 (100) | 8 (66.7) | ||
| Onset (yr) | 4.03b | .130 | |||
| < 20 | 6 (33.3) | 0 | 4 (33.3) | ||
| ≥ 20 | 12 (66.7) | 9 (100) | 8 (66.7) | ||
| Family history | 0.000b | > .999 | |||
| Negative | 12 (66.7) | 6 (66.7) | 8 (66.7) | ||
| Positive | 6 (33.3) | 3 (33.3) | 4 (33.3) | ||
| Distribution | 0.000b | > .999 | |||
| NSV | 6 (33.3) | 3 (33.3) | 4 (33.3) | ||
| SV | 12 (66.7) | 6 (66.7) | 8 (66.7) | ||
| Melanin | 9.85b | .007* | |||
| Absent | 9 (50.0) | 9 (100) | 4 (33.3) | ||
| Present | 9 (50.0) | 0 | 8 (66.7) | ||
| Dermal inflammation | 0.000b | > .999 | |||
| Mild | 12 (66.7) | 6 (66.7) | 8 (66.7) | ||
| Moderate | 6 (33.3) | 3 (33.3) | 4 (33.3) | ||
| HMB45 status | 1.11b | .570 | |||
| Negative | 9 (50) | 3 (33.3) | 4 (33.3) | ||
| Positive | 9 (50) | 6 (66.7) | 8 (66.7) | ||
| HMB45 (%) | 12.20a | .002* | |||
| Mean ± SD | 34.38 ± 34.59 | 6.66 ± 6.61 | 2.5 ± 4.52 | ||
| Median (range) | 30.00 (0–90) | 10.00 (0–15) | 4.52 (0–10) |
JAK, Janus kinase 1; SD, standard deviation; NSV, non-segmental vitiligo; SV, segmental vitiligo; HMB45, human melanoma black 45.
*
Significant.
a
Kruskal-Wallis test;
b
Fisher exact test.